Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Receivables (2016 - 2025)

Ironwood Pharmaceuticals' Receivables history spans 16 years, with the latest figure at $46.7 million for Q4 2025.

  • For Q4 2025, Receivables fell 42.98% year-over-year to $46.7 million; the TTM value through Dec 2025 reached $46.7 million, down 42.98%, while the annual FY2025 figure was $46.7 million, 42.98% down from the prior year.
  • Receivables for Q4 2025 was $46.7 million at Ironwood Pharmaceuticals, down from $120.4 million in the prior quarter.
  • Across five years, Receivables topped out at $138.0 million in Q4 2021 and bottomed at $39.8 million in Q1 2025.
  • The 5-year median for Receivables is $116.2 million (2022), against an average of $101.0 million.
  • The largest annual shift saw Receivables plummeted 51.17% in 2024 before it surged 57.97% in 2025.
  • A 5-year view of Receivables shows it stood at $138.0 million in 2021, then decreased by 5.8% to $130.0 million in 2022, then fell by 0.69% to $129.1 million in 2023, then tumbled by 36.56% to $81.9 million in 2024, then tumbled by 42.98% to $46.7 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Receivables are $46.7 million (Q4 2025), $120.4 million (Q3 2025), and $86.2 million (Q2 2025).